First patient in treatment in RhoVac's clinical phase IIb study in Germany
RhoVac AB ("RhoVac") announces today, on 23[rd] April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac").The first patient in Germany is in treatment in the clinical study, called BRaVac. This clinical trial phase IIb-study is a randomized, placebo-controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative treatment. The clinical phase IIb study is